These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 16821619)

  • 61. Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study.
    Marshall ME; Wolf M; O'Rourke M; Barnett TC; Crawford ED
    Cancer Biother Radiopharm; 1996 Apr; 11(2):119-23. PubMed ID: 10851528
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial.
    Fields-Jones S; Koletsky A; Wilding G; O'Rourke M; O'Rourke T; Eckardt J; Yates B; McGuirt C; Burris HA
    Ann Oncol; 1999 Nov; 10(11):1307-10. PubMed ID: 10631457
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Study on etoposide therapy of relapsing prostatic cancer patients].
    Moriyama M; Murai T; Kondoh I
    Hinyokika Kiyo; 1990 Jul; 36(7):777-81. PubMed ID: 2239575
    [TBL] [Abstract][Full Text] [Related]  

  • 64. 5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate.
    Shinohara N; Demura T; Matsumura K; Toyoda K; Kashiwagi A; Nagamori S; Ohmuro H; Ohzono S; Koyanagi T
    Prostate; 1998 Apr; 35(1):56-62. PubMed ID: 9537600
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
    Burk K; Gropp C; Rodeck G
    Urologe A; 1983 Sep; 22 Suppl():347-9. PubMed ID: 6415885
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A phase II evaluation of oral tamoxifen and intermittent intravenous vinblastine in hormone-refractory adenocarcinoma of the prostate.
    Pienta KJ; Redman BG; Esper PS; Flaherty LE
    Am J Clin Oncol; 1996 Oct; 19(5):500-3. PubMed ID: 8823479
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Re-induction of hormonal sensitivity in hormone-refractory prostate cancer--fact or fiction?
    Berry WR
    Nat Clin Pract Oncol; 2005 Apr; 2(4):180-1. PubMed ID: 16264926
    [No Abstract]   [Full Text] [Related]  

  • 68. A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. An Illinois Cancer Center Study.
    Kuzel TM; Tallman MS; Shevrin D; Braud E; Kilton L; Johnson P; Kozlowski J; Vogelzang NJ; Blough R; Benson AB
    Cancer; 1993 Sep; 72(6):1965-8. PubMed ID: 8364875
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Feasibility trial of a combination of vinorelbine, ifosfamide, fluorouracil and folinic acid (VIF regimen) in advanced urothelial cancer.
    Mahjoubi M; Kattan J; Droz JP; Philippot I; Pautier P; Boutan-Laroze A; Azab M; Theodore C
    Eur J Cancer; 1993; 29A(2):285-6. PubMed ID: 8422298
    [No Abstract]   [Full Text] [Related]  

  • 70. A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
    Bergan RC; Reed E; Myers CE; Headlee D; Brawley O; Cho HK; Figg WD; Tompkins A; Linehan WM; Kohler D; Steinberg SM; Blagosklonny MV
    Clin Cancer Res; 1999 Sep; 5(9):2366-73. PubMed ID: 10499606
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Suramin/epidoxorubicin association in hormone-refractory prostate cancer: preliminary results of a pilot phase II study.
    Miglietta L; Canobbio L; Granetto C; Vannozzi MO; Esposito M; Boccardo F
    J Cancer Res Clin Oncol; 1997; 123(7):407-10. PubMed ID: 9260594
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A phase II trial of deferoxamine in patients with hormone-refractory metastatic prostate cancer.
    Dreicer R; Kemp JD; Stegink LD; Cardillo T; Davis CS; Forest PK; See WA
    Cancer Invest; 1997; 15(4):311-7. PubMed ID: 9246151
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Chlorambucil and lomustine (CL56) in absolute hormone refractory prostate cancer: re-induction of endocrine sensitivity an unexpected finding.
    Shamash J; Dancey G; Barlow C; Wilson P; Ansell W; Oliver RT
    Br J Cancer; 2005 Jan; 92(1):36-40. PubMed ID: 15570307
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Response of hormone refractory prostate cancer to lycopene.
    Matlaga BR; Hall MC; Stindt D; Torti FM
    J Urol; 2001 Aug; 166(2):613. PubMed ID: 11458084
    [No Abstract]   [Full Text] [Related]  

  • 75. [Chemotherapy of hormone-resistent cancer of the prostate].
    Matveev BP; Bukharkin BV; Kalinin SA
    Urologiia; 2005; (4):20-3. PubMed ID: 16158740
    [TBL] [Abstract][Full Text] [Related]  

  • 76. CI-980 in advanced melanoma and hormone refractory prostate cancer.
    Ryan CW; Shulman KL; Richards JM; Kugler JW; Sosman JA; Ansari RH; Vokes EE; Vogelzang NJ
    Invest New Drugs; 2000 May; 18(2):187-91. PubMed ID: 10857996
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Discontinuous combination chemotherapy in extensive prostatic cancer].
    Chauvin HF
    J Urol Nephrol (Paris); 1973; 79(7):701-2. PubMed ID: 4780857
    [No Abstract]   [Full Text] [Related]  

  • 78. A Phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer: an Illinois cancer center study.
    Lokich J
    Cancer; 1994 Mar; 73(5):1536-7. PubMed ID: 8111726
    [No Abstract]   [Full Text] [Related]  

  • 79. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer.
    Zampino MG; Verri E; Locatelli M; Curigliano G; Ascione G; Sbanotto A; Rocca A; Verweij F; Matei V; Scardino E; Decobelli O; Goldhirsch A; Nolè F
    Anticancer Res; 2006; 26(3B):2375-80. PubMed ID: 16821619
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Vinorelbine and 5-fluorouracil bolus and/or continuous venous infusion plus levofolinic acid as second-line chemotherapy for metastatic breast cancer: an analysis of results in clinical practice of the Gruppo Oncologico Italia Meridionale (GOIM).
    Gebbia V; Caruso M; Borsellino N; Ajello R; Tirrito ML; Chiarenza M; Valenza R; Verderame F; Varvara F; Marrazzo A; Bajardi E; Ferrao F; Bordonaro R; Tralongo P
    Anticancer Res; 2006; 26(4B):3143-50. PubMed ID: 16886648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.